Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

Abstract

loading...

About

This paper, published in 1950, received 418 indexed citations. Written by Allan Lipton, Karim Fizazi, Alison Stopeck, David H. Henry, Janet E. Brown, Denise A. Yardley, Gary Richardson, Salvatore Siena, Pablo Maroto and Michael Clemens covering the research area of Oncology, Orthopedics and Sports Medicine and Molecular Biology. It is primarily cited by scholars working on Oncology (361 citations), Orthopedics and Sports Medicine (137 citations) and Radiology, Nuclear Medicine and Imaging (104 citations). Published in European Journal of Cancer.

Countries where authors are citing Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

Since Specialization
Citations

This map shows the geographic impact of Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials more than expected).

Fields of papers citing Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1016/j.ejca.2012.08.002.

Explore hit-papers with similar magnitude of impact

Breakdown of academic impact, for the paper Non-Steroidal Anti-Inflammatory Drugs Breakdown of academic impact, for the paper Numerical Methods using MATLAB Breakdown of academic impact, for the paper Polyphenols and Glycemic Control Breakdown of academic impact, for the paper Semiconstrained arthroplasty for the treatment of rheumatoid arthritis of the elbow. Breakdown of academic impact, for the paper The Grammar of English Predicate Complement Constructions Breakdown of academic impact, for the paper Allegories of Reading: Figural Language in Rousseau, Nietzsche, Rilke, and Proust Breakdown of academic impact, for the paper Rogue waves and rational solutions of the Hirota equation Breakdown of academic impact, for the paper Surface-Wave Devices for Signal Processing
Rankless by CCL
2026